STC 314
Alternative Names: STC-314; STC-3141; STC314 injectionLatest Information Update: 28 Aug 2024
At a glance
- Originator Grand Medical Pty Ltd.
- Class Anti-infectives; Anti-inflammatories
- Mechanism of Action Extracellular trap modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID-19 pneumonia; Sepsis
- No development reported Adult respiratory distress syndrome; SARS-CoV-2 acute respiratory disease; SARS-CoV-2 sepsis
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Adult-respiratory-distress-syndrome in China (IV, Infusion)
- 20 Nov 2023 Phase-II clinical trials in Sepsis in China (IV) (NCT06548854)
- 28 Jun 2023 No recent reports of development identified for phase-I development in SARS-COV-2 acute respiratory disease(In volunteers) in Australia (IV, Infusion)